BioArctic Sweden
21.08.2025 - 09:32:25Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET
For more information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Tel: + 46 704 10 71 80
This information was submitted for publication at 09:00 a.m. CET on August 21, 2025.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/9978/4221046/3620699.pdf
Invitation to presentation of BioArctic’s second quarter report for April â€" June 2025 on August 28
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-bioarctics-second-quarter-report-for-april--june-2025-on-august-28-at-9-30-am-cet-302535590.html
